BioSpace News Archive

The Board of Directors resolved on a rights issue of 75 MSEK, guaranteed to 80 percent, where the subscription period is ongoing

The new facility, which could be open by the end of 2021, will be supported by Harvard University, Massachusetts Institute of Technology, GE Healthcare Life Sciences, Alexandria Real Estate Equities and FUJIFILM Diosynth Biotechnologies.

FerGene, a Ferring subsidiary, was created to commercialize the drug in the U.S. and advance global development.

Aligos Therapeutics, Inc., a biotechnology company focused on the development of targeted therapies for hepatologic diseases and viral infections, including chronic hepatitis B, nonalcoholic steatohepatitis, and hepatocellular carcinoma, announced the appointment of Kathleen Sereda Glaub to the company’s board of directors.

Fortress Biotech, Inc. announced that it has priced an underwritten public offering of 262,500 shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock at a price of $20 per share, with expected gross proceeds to Fortress of approximately $5.3 million.

Pembrolizumab either used alone or in combination with chemotherapy was more effective than a standard cocktail of chemotherapy drugs in a study involving nearly 900 patients.

Promore Pharma AB has prepared a supplementary prospectus to the prospectus regarding the rights issue of approx.

Safety and efficacy evaluation will be performed on 36 patients from 3 hospitals located in US and Australia

The global pharmaceutical company and service partner Inceptua Group and Bendalis GmbH – German manufacturer of generic oncology drugs and special therapeutic agents, announce the signing of an exclusive clinical trial supply agreement for oncology generics.

Crohn’s & Colitis Foundation’s IBD Ventures award supports development of Thetis’ novel first-in-class Resolvin oral therapy (TP-317) for treatment of ulcerative colitis and Crohn’s disease